Modality
mRNA
MOA
IL-23i
Target
MDM2
Pathway
RNA Splicing
Bladder CaHCCCTCL
Development Pipeline
Preclinical
Mar 2025
→ Sep 2026
PreclinicalCurrent
NCT07824638
382 pts·HCC
2025-03→2026-09·Active
382 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-09-145mo awayInterim· HCC
Trial Timeline
Q2Q3Q42026Q2Q3
Preclinical
Active
Catalysts
Interim
2026-09-14 · 5mo away
HCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07824638 | Preclinical | HCC | Active | 382 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 |